SCHEMBL3968023

SCHEMBL3968023

[CH2]c1cc(Cl)nc2ccccc12

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAOA P21397 2/20 0.50
MAOB P27338 1/20 0.50
KDM4E B2RXH2 2/20 0.47
HTT P42858 2/20 0.46
USP2 O75604 1/20 0.46
KMT2A Q03164 3/20 0.42
MAPT P10636 4/20 0.42
IGF1R P08069 1/20 0.42
ALDH1A1 P00352 5/20 0.41
GAA P10253 3/20 0.41
CYP1A2 P05177 2/20 0.41
MEN1 O00255 1/20 0.41
CYP3A4 P08684 1/20 0.41
CYP2D6 P10635 1/20 0.41
CYP2C19 P33261 1/20 0.41
POLB P06746 1/20 0.41
TDP1 Q9NUW8 2/20 0.40
GLA P06280 1/20 0.40
CHRM2 P08172 1/20 0.40
ADRA2A P08913 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29420516 0.78 MAOA (0.54) MAOAMAOBKDM4EHTTUSP2
SCHEMBL397020 0.78 MAOA (0.54) MAOAMAOBKDM4EHTTUSP2
SCHEMBL6457778 0.75 KDM4E (0.51) MAOAMAOBKDM4EHTTUSP2
SCHEMBL832589 0.75 CYP1A2 (0.64) MAOAMAOBKDM4EHTTUSP2
SCHEMBL11343689 0.75 KMT2A (0.53) MAOAMAOBKDM4EHTTUSP2
SCHEMBL17508369 0.75 MAOA (0.56) MAOAMAOBKDM4EHTTUSP2
SCHEMBL3152061 0.75 KDM4E (0.40) MAOAMAOBKDM4EHTTKMT2A
SCHEMBL1845376 0.75 NCF1 (0.60) MAOAMAOBKDM4EHTTUSP2
SCHEMBL29980522 0.75 KDM4E (0.51) MAOAMAOBKDM4EHTTUSP2
SCHEMBL30517871 0.75 KMT2A (0.53) MAOAMAOBKDM4EHTTUSP2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2012170175-A1 COMPOSITIONS AND METHODS FOR TREATING, CONTROLLING, REDUCING, OR AMELIORATING INFLAMMATORY PAIN BAUSCH & LOMB INCORPORATED (US) 2012-12-13 WO disclosed
US-7595317-B2 Barbituric acid derivatives as inhibitors of TNF-α converting enzyme (TACE) and/or matrix metalloproteinases BRISTOL-MYERS SQUIBB COMPANY (US) 2009-09-29 US disclosed
US-7294624-B2 Osteoporosis; antiarthritic agents BRISTOL MYERS SQUIBB COMPANY (US) 2007-11-13 US disclosed
US-20070167451-A1 BARBITURIC ACID DERIVATIVES AS INHIBITORS OF TNF-alpha CONVERTING ENZYME (TACE) AND/OR MATRIX METALLOPROTEINASES DUAN JINGWU 2007-07-19 US disclosed
US-20050197350-A1 Novel quinoline, tetrahydroquinazoline, and pyrimidine derivatives and methods of treatment related to the use thereof TAISHO PHARMACEUTICAL CO., LTD. 2005-09-08 US disclosed
WO-2003053941-A2 BARBITURIC ACID DERIVATIVES AS INHIBITORS OF TNF-ALPHA CONVERTING ENZYME (TACE) AND/OR MATRIX METALLOPROTEINASES BRISTOL-MYERS SQUIBB COMPANY (US) 2003-07-03 WO disclosed
WO-2003040103-A1 β-SULFONE DERIVATIVES AS INHIBITORS OF MATRIX METALLOPROTEINASES AND/OR TNF-α CONVERTING ENZYME (TACE) BRISTOL-MYERS SQUIBB COMPANY (US) 2003-05-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070167451-A1 BARBITURIC ACID DERIVATIVES AS INHIBITORS OF TNF-alpha CONVERTING ENZYME (TACE) AND/OR MATRIX METALLOPROTEINASES TNF, MMP9, MMP3 MAOA 175/4885MAOB 99/4885KDM4E 2397/4885
US-20050197350-A1 Novel quinoline, tetrahydroquinazoline, and pyrimidine derivatives and methods of treatment related to the use thereof HCRTR2, MCHR1, MCHR2 MAOA 272/4885MAOB 168/4885KDM4E 1190/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.